The Company will initially discover and develop novel orally delivered, small molecule-based therapies targeting incretins and other class B GPCRs. Nick Traggis, President and Founder of Ambrosia, added, “While this is a very active space, there is significant science yet to be understood and plenty of opportunity to improve upon existing GLP-1 based drugs. I’m proud of the work our founding science team has already done and look forward to using this financing to scale up our drug discovery efforts.”
About Ambrosia Biosciences Inc.
Ambrosia Biosciences Inc. is a privately held drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. For more information, please visit www.ambrosiabiosciences.com
Media Contact
Faith Clauson
(720) 841 – 3816
Media Contact
Faith Clauson, Ambrosia Biosciences, 1 7208413826, [email protected], https://ambrosiabiosciences.com/
SOURCE Ambrosia Biosciences
